News Release

Latest News

February 3, 2017: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2017
January 11, 2017: Conclusion of Agreement on Business Alliance for Sale of Hand-Sanitizers
December 28, 2016: Change in Consolidated Subsidiaries (Share Transfer)
November 18, 2016: Release of DESALEX Tablets 5mg for treatment of allergic diseases
November 7, 2016: Consolidated Financial Results (For the second Quarter Ended Sep 30,2016)- Supplementary Information
November 7, 2016: Summary of Consolidated Financial Results (For the second Quarter Ended Sep 30,2016)［Japanese Standard］
October 17, 2016: Release of Alcohol free hand-sanitizer Noahtect
October 4, 2016: LAUNCH OF URITOS TABLETS FOR OVERACTIVE BLADDER IN THAILAND
September 28, 2016: MSD K.K. receives manufacturing and marketing approval for DESALEX Tablets 5mg for treatment of allergic diseases
September 15, 2016: MSD and Kyorin Sign Agreement on Co-Promotion of Therapeutic Agent for Allergic Rhinitis, NASONEX Nasal
September 1, 2016: Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
July 29, 2016: Consolidated Financial Results (For the First Quarter Ended June 30,2016)- Supplementary Information
July 29, 2016: Summary of Consolidated Financial Results (For the First Quarter Ended June 30, 2016) [Japanese Standard]
July 11, 2016: Kyorin Pharmaceutical and Kaken Pharmaceutical signed a Contract for the co-promotion of the anti-allergic therapeutic agent "desloratadine"
June 20, 2016: NHI Drug Price Listing and Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
June 1, 2016: Release of Eklira 400μg Genuair 60 inhalations, a treatment for COPD
May 25, 2016: MSD's investigational antiallergic agent desloratadine to be exclusively marketed by Kyorin
May 24, 2016: Formulation of the New Medium-Term Business Plan "HOPE 100: Stage 2"
May 12, 2016: Supplementary information (May 12, 2016)
May 12, 2016: Summary of consolidated financial results (May 12, 2016)
March 30, 2016: Kyorin and Kissei signed an Agreement for Co-Development and Co-Marketing of KRP-114V
February 23, 2016: Announcement Regarding Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
February 3, 2016: Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2015)［Japanese Standard］
February 3, 2016: Consolidated Financial Results (For the third Quarter Ended Dec 31,2015)- Supplementary Information
February 3, 2016: Revision of Consolidated Financial Forecasts
February 3, 2016: Termination of License Concerning COPD Therapeutic Drug KRP-AB1102F
January 27, 2016: KYORIN Medical Supply and P.T. Meiji Indonesian Pharmaceutical Industries Sign Basic Agreement for RUBYSTA® Multi-Purpose Disinfectant Cleaner in Indonesia
December 11, 2015: Release of KIPRES OD Tablets 10mg, a treatment for bronchial asthma and allergic rhinitis
December 11, 2015: NHI Drug Price Listing of PENTASA Granules 94%, a treatment for Ulcerative Colitis and Crohn's Disease
December 9, 2015: Kyorin Pharmaceutical Signed a License Agreement with Bristol-Myers Squibb
November 5, 2015: KYORIN Pharmaceutical and PeptiDream Reach Agreement for Peptide Discovery Collaboration
November 5, 2015: Consolidated Financial Results (For the second Quarter Ended Sep 30,2015)- Supplementary Information
November 5, 2015: Summary of Consolidated Financial Results (For the second Quarter Ended Sep 30,2015)［Japanese Standard］
October 15, 2015: MSD Submits New Drug Application for Antiallergic Agent, Desloratadine to be Co-marketed with Kyorin
August 31, 2015: KYORIN Pharmaceutical and Synmosa Biopharma Corporation Sign License Agreement of Imidafenacin in Taiwan
August 17, 2015: Approval received for PENTASA Granules 94%, a treatment for Ulcerative Colitis and Crohn's Disease
August 17, 2015: Approval received for KIPRES OD Tablets 10mg, a treatment for bronchial asthma and allergic rhinitis
July 30, 2015: Summary of Consolidated Financial Results (For the First Quarter Ended June 30,2015)［Japanese Standard］
July 30, 2015: Consolidated Financial Results (For the First Quarter Ended June 30,2015)- Supplementary Information
May 20, 2015: Release of Eklira Genuair, a treatment for COPD
May 13, 2015: Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2015) [Japanese Standard]
March 26, 2015: Genuair, a dry powder inhaler for COPD treatment, selected for iF UNIVERSAL DESIGN award for 2015
March 26, 2015: Approval received for Eklira Genuair, a treatment for COPD
February 12, 2015: Signing of Co-marketing Agreement for multi-purpose disinfectant cleaner RUBYSTA
February 2, 2015: Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)［Japanese Standard］
February 2, 2015: Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)- Supplementary Information
December 1, 2014: Release of Flutiform® 50 Aerosol - 120 inhalations, Flutiform® 125 Aerosol - 120 inhalations , a combination drug for asthma treatment
November 27, 2014: Signing of Co-Marketing Agreement on Investigational Antiallergic Agent, Desloratadine for Japan
November 4, 2014: Summary of consolidated financial results (November 4, 2014)
November 4, 2014: Consolidated Financial Results (For the Second Quarter Ended september 30,2014)- Supplementary Information